Press releases

Columbus, OH; Wilmington, MA – April 2, 2025 – CAS, a division of the American Chemical Society specializing in scientific knowledge management, and Charles River Laboratories International, Inc., a leading, global non-clinical drug discovery and development partner, today announced the expansion of their collaboration on accelerating drug discovery innovation.

This step marks a new chapter in the longstanding relationship between CAS and Charles River. The two organizations will co-develop workflows and processes to maximize the impact of CAS scientific technology solutions like CAS SciFinder^® on Charles River's innovation process. A newly established task force will facilitate regular engagement between the organizations, providing feedback to guide future developments.  

“We value our long-term relationship with CAS and their ongoing support of our mission to bring therapies to patients safely and efficiently,” said Charles Baker-Glenn, Associate Director, Small Molecule Drug Discovery, Charles River. “The continual drive to introduce enhancements to their solutions and their commitment to collaboration make CAS an indispensable partner in our research efforts.”

Charles River and other contract research organizations (CROs) play a critical role in accelerating drug discovery and development. CAS continuously enhances its scientific technology solutions to meet the unique needs of these organizations. Recent improvements in retrosynthesis functionality, the addition of searchable analytical methods and formulations content, and the introduction of the CAS BioFinder™ are examples of the innovation CAS has recently provided to life sciences research.

“Broadening our collaboration with Charles River reaffirms the CAS commitment to delivering cutting-edge scientific technology solutions to the CRO market,” said Dennis W. McCullough, Global Vice President Customer Success at CAS. “By engaging in a meaningful collaboration, CAS aims to empower scientists and business leaders at Charles River to accelerate drug discovery and deliver critical therapies to patients.”

Charles River, recognized globally for its excellence in drug discovery and development programs, shares the CAS vision for advancing scientific discovery. By leveraging the CAS technology solutions and custom services, Charles River is positioned to provide industry-leading scientific support to clients and enhance its capabilities across the drug discovery and development process.

About CAS

CAS connects the world's scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today’s complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. CAS is a division of the American Chemical Society. Connect with us at cas.org.

About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.